Abstract
diabetic nephropathy (DN) remains the single most common cause of end-stage kidney disease, necessitating dialysis or transplantation, in the Western world. Hence, novel therapies beyond tight blood pressure and glycemic control are required to slow or reverse progression of nephropathy in patients
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
